Heidi Overton, Trump's 3rd FDA Pick, Faces Senate Confirmation Fight

For regulatory lawyers and compliance teams, the Overton nomination is not just a personnel move — it previews the administrative-law battles ahead. A commissioner whose signature policies, from a rewritten childhood vaccine schedule to state-level 'gold standard' recommendations that physicians say lack scientific support, will likely trigger rulemaking challenges, state preemption disputes, and APA litigation. With the CDC confirmation of Erica Schwartz passing narrowly, the Senate path for Trump's third-choice FDA pick is a live test of confirmation math.

President Donald Trump said Wednesday, Aug. 19, 2026, that he will nominate Dr. Heidi Overton, deputy director of the White House Domestic Policy Council, to be the next commissioner of the Food and Drug Administration. The move, delivered in a social-media post, ends a search that cycled through at least three candidates and hands the agency's top job to a physician who has become one of the administration's most visible and controversial voices on health policy. Trump called Overton a 'ROCKSTAR' and quoted Health and Human Services Secretary Robert F. Kennedy Jr. saying she is 'ALWAYS RIGHT.'

“

Heidi Overton, deputy director of the White House Domestic Policy Council, to be the next commissioner of the Food and Drug Administration.

Overton is not a conventional regulator. She joined the White House at the start of Trump's second term and, according to STAT News, previously led the health policy center at the America First Policy Institute, the conservative think tank closely aligned with the administration. Her White House portfolio has included redesigning the food pyramid, revising the childhood vaccine schedule, and negotiating drug-pricing deals with pharmaceutical companies. That is a strikingly broad mandate, and it places her at the center of the administration's 'Make America Healthy Again' agenda while exposing her to sharp criticism from the mainstream medical establishment.

The clearest flashpoint is vaccines. On Aug. 10, 2026, Overton stood beside Trump when he signed an executive order aimed at reducing the number of universally recommended childhood vaccinations. At that event she urged 'blue states' to adopt the administration's 'gold standard' recommendations, a position many physicians say is not supported by current science. If confirmed, she would take charge of the very agency that evaluates vaccine safety and effectiveness — a prospect that has drawn warnings from public-health advocates and lingering skepticism from some MAHA-aligned figures who question her record.

The nomination also reflects turbulence inside the agency. Overton would replace Dr. Marty Makary, who resigned in May 2026 after clashes with the White House. She was, by the account of a senior administration official, the third choice for the job: former Rep. Brad Wenstrup, R-Ohio, declined, as did acting Commissioner Kyle Diamantas, who cited his young children and other personal reservations. The administration was still interviewing candidates as recently as Tuesday, Aug. 18, the day before Trump's announcement. A resignation, two declinations, and a late-breaking pick signal an agency and a confirmation process under strain.

The timing compounds the stakes. The announcement arrives during a multistate cyclospora outbreak that has raised fresh concerns about the safety of the nation's food supply. Cyclospora, a foodborne parasite often linked to contaminated produce, triggers recalls, traceback investigations, and consumer alerts. A new commissioner would be expected to stand up the agency's food-safety response immediately, even while navigating Senate confirmation and assembling a leadership team.

For the regulated industries — biopharma, medical devices, and food — the commissioner sets the practical tempo of regulation: which applications get priority, how aggressively drug prices are negotiated, how vaccine policy is communicated, and how quickly the agency responds to public-health emergencies. Overton's history of negotiating pricing deals with pharmaceutical companies suggests a more assertive posture on drug costs than industry has sometimes seen. Her vaccine-schedule work points toward continued friction with professional medical organizations. Her food-pyramid redesign hints at a broader reshaping of the agency's public-health guidance role.